Biomass from Fusarium Venenatum and Preliminary Characterization of Bioactives: Exploration of Hypolipidemic Potential
Journal Title: Open Access Journal of Pharmaceutical Research - Year 2017, Vol 1, Issue 6
Abstract
Fusarium venenatum derived mycoprotein (biomass) marketed under the trade name Quorn has been designated as a source of first class protein with low cholesterol. Our previous study, demonstrates the significant anti-hyperlipidemic potential of biomass in acute Triton X-100 induced hyperlipidemic model in rats and anti-oxidant activity by DPPH assay. The biomass was produced through cost effective fermentation process in Vogel’s mineral medium using sucrose as the carbon source optimized using Central Composite Response Surface Design (CCRSD). In continuation to our previous reported work, in the current study the hypolipidemic potential of biomass was studied in the chronic high fat diet induced hyperlipidemic model in rats. The high fat diet fed rats showed significant increase in plasma lipid levels [total cholesterol (TC), triglycerides (TG), very low density lipoproteins (VLDL), low density lipoproteins (LDL)] with decreased high density lipoproteins (HDL) levels. Biomass (100, 200 and 400 mg/kg) and simvastatin (10 mg/kg) administered orally reduced the elevated serum lipids (TC, TG, VLDL, LDL), restored the decreased HDL and improved the atherogenic index (p<0.01). Also the treatment with biomass decreased the liver enzymes levels (SGOT, SGPT) comparable to standard treated group. The biomass treatment also improved histoarchitecture of hepatocytes in hyperlipidemic rats. The acute oral toxicity study carried out as per OECD guidelines demonstrated the safety of the biomass. LC-MS analysis of methanolic extract of biomass showed two major peaks (Compound 1: m/e 209.10 and Compound 2: m/e 329.25). Spectral matching with NIST libraries indicated that compound 2 may be structurally similar to pregnenolone, a naturally occurring steroid. Also, compound 1 may be 4- aminothiophenol, N,S,-diacety (m/e 209.10). These probable bioactives, exhibits varied biological activities including for the treatment of inflammation, and its related disorders as suggested by literature reports. In conclusion, the study proves the hypolipidemic potential of biomass derived from Fusarium venenatum in preclinical acute and chronic animal models. Further investigations to isolate the bioactives and elucidate the probable mechanisms and role in triggering hypolipidemic activity need to be undertaken.
Authors and Affiliations
Patil SD, Shetane TD, Singha RG, Choudhary DM, Nanda RK, D’souza OR and Thomas AB*
Keywords
Related Articles
- EP ID EP745875
- DOI 10.23880/oajpr-16000136
- Views 1
- Downloads 0
Phytochemical Analysis of Traditional Medicinal Plants and their Antimicrobial Activity: An Experience from North East India
Introduction: Phytochemicals are non-nutritive, chemical compounds that occur naturally on plants and have diverse protective properties .Most Phytochemicals like carotenoids, flavonoids and polyphenols have antimicrobia...
To Study the Effect of Swertiamarin in Animal Model of Huntington’s Disease
Objective: The Data suggest that swertiamarin has antioxidant activity and they modulate neurotoxicity induced oxidative impairments in the brain and can be effectively employed as a neuroprotective. The preclinical find...
The Influence of Cholinergic System on Rheumatoid Arthritis
Rheumatoid arthritis is one of the most prevalent immune-mediated arthritis and is categorized as a chronic, inflammatory and autoimmune disease, which mainly affects the cartilage, synovial joint, and bone, the causes o...
Tamoxifen: Pharmacokinetics and Pharmacodynamics
Tamoxifen is the hormone therapy of choice in pre-menopausal estrogen receptor positive breast cancer in women and sometimes in post-menopausal women. The environmental and genetic factors widely affect the pharmacokinet...
Transdermal Delivery Offer for Low Dose Acetylsalicylic Acid
The use of Acetyl Salicylic Acid (ASA) in the secondary prevention of cardio vascular diseases is well known. Orally administered ASA is rapidly metabolized to its principal metabolite Salicylic Acid (SA) in the gastroin...